Literature DB >> 20051972

Antifibrotic therapies--emerging biomarkers as treatment end points.

Jayant A Talwalkar1.   

Abstract

The emergence of novel pharmacologic therapies for hepatic fibrosis holds promise for the management of this condition. Furthermore, novel, biological indices-in addition to liver biopsy-may improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20051972     DOI： 10.1038/nrgastro.2009.197

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  26 in total

1.  Elastography for the non-invasive assessment of liver disease: limitations and future developments.

Authors:  Francesco Vizzutti; Umberto Arena; Fabio Marra; Massimo Pinzani
Journal:  Gut       Date:  2009-02       Impact factor: 23.059

2.  Liver biopsy: the best, not the gold standard.

Authors:  Pierre Bedossa; Fabrice Carrat
Journal:  J Hepatol       Date:  2008-11-06       Impact factor: 25.083

3.  Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

Authors:  Laurent Huwart; Christine Sempoux; Eric Vicaut; Najat Salameh; Laurence Annet; Etienne Danse; Frank Peeters; Leon C ter Beek; Jacques Rahier; Ralph Sinkus; Yves Horsmans; Bernard E Van Beers
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

4.  Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.

Authors:  Nimer Assy; M Paizi; D Gaitini; Y Baruch; G Spira
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

5.  Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C.

Authors:  A K P Lim; S D Taylor-Robinson; N Patel; R J Eckersley; R D Goldin; G Hamilton; G R Foster; H C Thomas; D O Cosgrove; M J K Blomley
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 6.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

Review 7.  In vivo detection of apoptosis.

Authors:  Francis G Blankenberg
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

8.  Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Authors:  Robert J Fontana; Herbert L Bonkovsky; Deepa Naishadham; Jules L Dienstag; Richard K Sterling; Anna S F Lok; Grace L Su
Journal:  Clin Gastroenterol Hepatol       Date:  2008-11-07       Impact factor: 11.382

Review 9.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Authors:  J P B O'Connor; A Jackson; G J M Parker; G C Jayson
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

Review 10.  Circulating endothelial cells in oncology: pitfalls and promises.

Authors:  M H Strijbos; J W Gratama; J Kraan; C H Lamers; M A den Bakker; S Sleijfer
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640
View more
  7 in total

1.  Holeuryhalinity and its mechanisms in a cirriped crustacean, Balanus improvisus.

Authors:  H J Fyhn
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1976-01

Review 2.  Evolving challenges in hepatic fibrosis.

Authors:  Scott L Friedman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

Review 3.  Non-invasive markers for hepatic fibrosis.

Authors:  Ancha Baranova; Priyanka Lal; Aybike Birerdinc; Zobair M Younossi
Journal:  BMC Gastroenterol       Date:  2011-08-17       Impact factor: 3.067

4.  Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis.

Authors:  Toni Segovia-Silvestre; Vedrana Reichenbach; Guillermo Fernández-Varo; Efstathios Vassiliadis; Natasha Barascuk; Manuel Morales-Ruiz; Morten A Karsdal; Wladimiro Jiménez
Journal:  Fibrogenesis Tissue Repair       Date:  2011-08-03

5.  Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease.

Authors:  Xi Li; Qun-Yan Yao; Hong-Chun Liu; Qian-Wen Jin; Bei-Li Xu; Shun-Cai Zhang; Chuan-Tao Tu
Journal:  J Cell Mol Med       Date:  2017-04-05       Impact factor: 5.310

6.  Real-time monitoring of liver fibrosis through embedded sensors in a microphysiological system.

Authors:  Hafiz Muhammad Umer Farooqi; Bohye Kang; Muhammad Asad Ullah Khalid; Abdul Rahim Chethikkattuveli Salih; Kinam Hyun; Sung Hyuk Park; Dongeun Huh; Kyung Hyun Choi
Journal:  Nano Converg       Date:  2021-02-02

7.  A Herbal Formula, CGXII, Exerts Antihepatofibrotic Effect in Dimethylnitrosamine-Induced SD Rat Model.

Authors:  Hyo-Seon Kim; Hyeong-Geug Kim; Hye-Won Lee; Sung-Bae Lee; Jin-Seok Lee; Hwi-Jin Im; Won-Yong Kim; Dong-Soo Lee; Chang-Gue Son
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-29       Impact factor: 2.629
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.